M.D., Academy of Medicine, Bialystok, Poland, 1984
Anatomic Pathology, Mallory Institute of Pathology, Boston University School of Medicine, Boston MA, 1989-1991
Clinical Pathology, University Hospital, Boston University School of Medicine, Boston, MA, 1991-1993
Cytopathology, Mallory Institute of Pathology, Boston University School of Medicine, Boston, MA, 1993-1994
Dr. Moroz received his MD from the Academy of Medicine in Bialystok, Poland. He completed his anatomic pathology training at the Mallory Institute of Pathology, Boston University School of Medicine in Boston, followed by clinical pathology training at the University Hospital at Boston University School of Medicine. Dr. Moroz completed fellowship training in cytopathology at the Mallory Institute of Pathology at Boston University School of Medicine in 1994. He is board-certified in anatomic and clinical pathology (1993) and cytopathology (1994) by the American Board of Pathology. He is a fellow of the College of American Pathologists. Dr. Moroz joined Tulane University School of Medicine in 1994. He is actively participating in the cytopathology and surgical pathology services of the department. His research interests include breast and prostate cancer, and prognostic tumor markers. He is co-directing the Biospecimen Core Laboratory of the Louisiana Cancer Research Consortium.
1993, American Board of Pathology, Anatomic and Clinical Pathology
1994, American Board of Pathology, Cytopathology
Cytopathology and Surgical Pathology
Breast Cancer Pathology
Prognostic Tumor Markers
Aydin Y, Chedid M, Chava S, Danielle Williams D, Liu S, Hagedorn CH, Sumitran-Holgersson S, Reiss K, Moroz K, Lu H, Balart LA, Dash S. Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture. Sci Rep. 2017 Aug 23;7(1):9223. doi: 10.1038/s41598-017-10087-6.
Chava S, Lee C, Aydin Y, Chandra PK, Dash A, Chedid M, Thung SN, Moroz K, Wu T, Nayak NC, Dash S. Chaperone-mediated autophagy compensates for impaired macroautophagy in the cirrhotic liver to promote hepatocellular carcinoma. Oncotarget. 2017 Jun 20;8(25):40019-40036. doi: 10.18632/oncotarget.16685.
Moustafa AA, Ziada M, Elshaikh A, Datta A, Kim H, Moroz K, Srivastav S, Thomas R, Silberstein JL, Moparty K, Salem FE, El-Habit OH, Abdel-Mageed AB. Identification of microRNA signature and potential pathway targets in prostate cancer. Exp Biol Med (Maywood). 2017 Mar;242(5):536-546. doi: 10.1177/1535370216681554. Epub 2016 Dec 8.
Abd Elmageed ZY, Sholl AB, Tsumagari K, Al-Qurayshi Z, Basolo F, Moroz K, Boulares AH, Friedlander P, Miccoli P, Kandil E. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer. Surgery. 2017 Apr;161(4):1122-1128. doi: 10.1016/j.surg.2016.06.081. Epub 2016 Dec 2.
Al-Qurayshi Z, Deniwar A, Thethi T, Mallik T, Srivastav S, Murad F, Bhatia P, Moroz K, Sholl AB, Kandil E. Association of Malignancy Prevalence with Test Properties and Performance of the Gene Expression Classifier in Indeterminate Thyroid Nodules. JAMA Otolaryngol Head Neck Surg. 2016 Dec 15. doi: 10.1001/jamaoto.2016.3526. [Epub ahead of print]. PMID:27978562
Seijo E, Lima D, Iriabho E, Almeida J, Monico J, Echeverri M, Gutierrez S, Flores I, Lee JH, Fisher K, Grizzle WE, Sica GL, Butler C, Hicks C, Meade CD, Sodeke SO, Moroz K, Coppola D, Munoz-Antonia T. Construction and Validation of a Multi-Institutional Tissue Microarray of Invasive Ductal Carcinoma from Racially and Ethnically Diverse Populations. Cancer Control. 2016 Oct;23(4):383-389.
Zhang J, Baddoo M, Han C, Strong MJ, Cvitanovic J, Moroz K, Dash S, Flemington EK, Wu T. Gene network analysis reveals a novel 22-gene signature of carbon metabolism in hepatocellular carcinoma. Oncotarget. 2016 Aug 2;7(31):49232-49245. doi: 10.18632/oncotarget.10249.
Deniwar A, Hammad AY, Ali DB, Alsaleh N, Lahlouh M, Sholl AB, Moroz K, Aslam R, Thethi T, Kandil E, MD. Optimal Timing for a Repeat FNA Biopsy of Thyroid Nodule Following an Initial Non-Diagnostic FNA. The American Journal of Surgery. doi:10.1016/j.amjsurg.2016.04.010
Doucet ME, Bloomhardt HM, Moroz K, Lindhurst MJ, Biesecker LG. Lack of mutation-histopathology correlation in a patient with Proteus syndrome. Am Am J Med Genet A. 2016 Jun;170(6):1422-1432. doi: 10.1002/ajmg.a.37612. Epub 2016 Apr 26.
Yang Y, Jia D, Kim H, Abd Elmageed ZY, Datta A, Davis R, Srivastav S, Moroz K, Crawford B, Moparty K, Thomas R, Hudson RS, Ambs S, Abdel-Mageed AB. Dysregulation of microRNA-212 Promotes Castration Resistance via hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer. Clin Cancer Res. 2015 Nov 9. pii: clincanres.1606.2015
Deniwar A, Hambleton C, Thethi T, Moroz K, Kandil E. Examining the Bethesda criteria risk stratification of thyroid nodules. Pathol Res Pract. 2015 May;211(5):345-8.
Ibrahim Y, Mohamed SE, Deniwar A, Al-Qurayshi ZH, Khan AN, Moroz K, Friedlander P, Kandil E. The impact of thyroid nodule size on the risk of malignancy in follicular neoplasms. Anticancer Res. 2015 Mar;35(3):1635-9.
Kang HJ, Park JH, Chen W, Kang SI, Moroz K, Ladanyi M, Lee SB. EWS-WT1 oncoprotein activates neural reprogramming factor ASCL1 and promotes neural differentiation. Cancer Res. 2014 Aug 15;74(16):4526-35.
McCarthy M, Auda G, Agrawal S, Taylor A, Backstrom Z, Mondal D, Moroz K, Dash S. In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer. Exp Mol Pathol. Exp Mol Pathol. 2014 Aug;97(1):6-15.
Bao L, Chandra PK, Moroz K, Zhang X, Thung SN, Wu T, Dash S. Impaired autophagy response in human hepatocellular carcinoma. Exp Mol Pathol. 2014 Apr;96(2):149-54.
Abd Elmageed ZY, Yang Y, Thomas R, Ranjan M, Mondal D, Moroz K, Fang Z, Rezk BM, Moparty K, Sikka SC, SartorO, Abdel-Mageed AB. Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells. 2014 Apr;32(4):983-97.